- Document Number:
20220409718
- Appl. No:
17/823566
- Application Filed:
August 31, 2022
- نبذة مختصرة :
The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use in safe immunizations to protect against a variety of pathogens. The invention also relates to multivalent compositions or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making an using said recombinant viral vectors.
- Claim:
1-21. (canceled)
- Claim:
22. A recombinant Herpesvirus of Turkey (HVT) genome comprising: a. a nucleotide sequence coding for a heterologous antigen from an Infectious Bursal Disease Virus inserted into the intergenic loci UL 35/UL 36 in the unique long region of the HVT genome: and b. a nucleotide sequence coding for a heterologous antigen from a Newcastle Disease Virus inserted at the UL55/Gene 3 site in the unique long region (UL) of the HVT genome.
- Claim:
23. The recombinant Herpesvirus of Turkey (HVT) genome of claim 22 wherein the nucleotide sequence coding for a heterologous antigen from an Infectious Bursal Disease Virus is selected from the group consisting of: the nucleotide sequence coding for the VP2 protein; the nucleotide sequence coding for the VP3 protein; and the nucleotide sequence coding for the VP4 protein of the Infectious Bursal Disease Virus.
- Claim:
24. The recombinant Herpesvirus of Turkey (HVT) genome of claim 23 wherein the nucleotide sequence coding for a heterologous antigen from an Infectious Bursal Disease Virus comprises the nucleotide sequence coding for the VP2 protein.
- Claim:
25. The recombinant Herpesvirus of Turkey (HVT) genome of claim 24 wherein the nucleotide sequence coding for the VP2 protein from an Infectious Bursal Disease Virus comprises a nucleotide sequence comprising at least about 80% sequence identity to the nucleotide sequence that comprises either SEQ ID NO.5 or SEQ ID NO.10.
- Claim:
26. The recombinant Herpesvirus of Turkey (HVT) genome of claim 22 wherein the nucleotide sequence coding for a heterologous antigen from a Newcastle Disease Virus is selected from the group consisting of: the nucleotide sequence coding for the F/HN chimera protein; the nucleotide sequence coding for the F protein; the nucleotide sequence coding for the NP protein; the nucleotide sequence coding for the P protein; the nucleotide sequence coding for the M protein; the nucleotide sequence coding for the HN protein; and the nucleotide sequence coding for the L protein of the Newcastle Disease Virus.
- Claim:
27. The recombinant Herpesvirus of Turkey (HVT) genome of claim 26 wherein the nucleotide sequence coding for a heterologous antigen from a Newcastle Disease Virus comprises the nucleotide sequence coding for the F protein.
- Claim:
28. The recombinant Herpesvirus of Turkey (HVT) genome of claim 27 wherein the nucleotide sequence coding for the F protein from a Newcastle Disease Virus comprises a nucleotide sequence comprising at least about 80% sequence identity to the nucleotide sequence that comprises SEQ ID NO. 3.
- Claim:
29. The recombinant Herpesvirus of Turkey (HVT) genome of claim 22 further comprising the nucleotide sequence of one or more promoters.
- Claim:
30. The recombinant Herpesvirus of Turkey (HVT) genome of claim 29 wherein the one or more promoters are selected from the group consisting of: immediate early cytomegalovirus human (hCMV) promoter: guinea pig immediate early CMV promoter; murine immediate early CMV promoter; Pec promoter; β-chicken actin promoter; SV40 promoter; Pseudorabies Virus promoters of glycoprotein X promoter; Herpes Simplex Virus-1 alpha 4 promoter; Marek's Disease Virus promoters of glycoproteins gA, gC, gB, gE, or gl promoter; Infectious Laryngotracheitis Virus promoters of glycoprotein gB, gE, gl, gD promoter; and Bovine Herpesvirus 1/1 VP8 promoter.
- Claim:
31. The recombinant Herpesvirus of Turkey (HVT) genome of claim 30 wherein the nucleotide sequences for one or more promoters comprise the nucleotide sequences for the immediate early cytomegalovirus human promoter (hCMV) comprising the nucleotide sequence that comprises SEQ ID NO. 1 and the murine immediate early CMV promoter comprising SEQ ID NO.2.
- Claim:
32. The recombinant Herpesvirus of Turkey (HVT) genome of claim 22 further comprising one or more nucleotide sequences that encode a poly A signal.
- Claim:
33. The recombinant Herpesvirus of Turkey (HVT) genome of claim 32 wherein the one or more nucleotide sequences that encode a poly A signal comprise either the SV40 poly A tail comprising the nucleotide sequence comprising SEQ ID NO. 12, or the Bovine Growth Hormone (BGH) poly A tail comprising the nucleotide sequence comprising SEQ ID NO. 6.
- Claim:
34. A recombinant Herpesvirus of Turkey (HVT) genome comprising: a. a nucleotide sequence coding for an Infectious Bursal Disease Virus VP2 protein comprising at least 80% sequence identity to the nucleotide sequence that comprises either SEQ ID NO.5 or SEQ ID NO. 10 inserted into the intergenic loci UL 35/UL 36 in the unique long region of the HVT genome; and b. a nucleotide sequence coding for the Newcastle Disease Virus F protein comprising at least 80% sequence identity to the nucleotide sequence that comprises SEQ ID NO. 3 inserted at the UL55/Gene 3 site in the unique long region (UL) of the HVT genome.
- Claim:
35. A recombinant Herpesvirus of Turkey (HVT) genome comprising: a. an expression cassette inserted into the intergenic loci UL 35/UL 36 of the unique long region of the HVT genome comprising, in order: a nucleotide sequence for the human cytomegalovirus promoter comprising SEQ ID NO. 1, the nucleotide sequence coding for the Infectious Bursal Disease Virus VP2 protein comprising a nucleotide sequence comprising at least 80% sequence identity to the nucleotide sequences comprising either SEQ ID NO.5 or SEQ ID NO. 10, and the nucleotide sequence coding for the Bovine Growth Hormone (BGH) poly A tail comprising SEQ ID NO.6; and b. an expression cassette inserted into the UL55/Gene 3 site of the unique long region of the HVT genome comprising, in order: the nucleotide sequence for the murine cytomegalovirus promoter comprising SEQ ID NO. 2; the nucleotide sequence coding for the Newcastle Disease Virus F protein comprising a nucleotide sequence comprising at least 80% sequence identity to the nucleotide sequence comprising SEQ ID NO. 3, and the nucleotide sequence coding for the SV40 poly A tail comprising SEQ ID NO. 12.
- Claim:
36. A recombinant Herpesvirus of Turkey Virus (HVT) comprising the HVT genome of any one of claim 22, 34 or 35.
- Claim:
37. An isolated nucleotide sequence encoding the recombinant Herpesvirus of Turkey Virus of claim 36.
- Claim:
38. A cell line that produces the recombinant Herpesvirus of Turkey Virus of claim 36.
- Claim:
39. A vaccine composition comprising the recombinant Herpesvirus of Turkey Virus of claim 36 further comprising a pharmaceutically acceptable carrier, excipient or adjuvant.
- Claim:
40. A kit comprising the vaccine of claim 39.
- Claim:
41. A method of preventing Infectious Bursal Disease, Newcastle Disease and Marek's Disease in an avian by administering an effective amount of the vaccine of claim 39.
- Claim:
42. The method of claim 41 wherein the route of administration is performed by spray administration, in ovo administration, subcutaneous administration, intramuscular administration, oral administration or nasal administration.
- Claim:
43. The method of claim 42, wherein the administration route comprises in ovo administration.
- Claim:
44. The method of claim 42 wherein the administration route comprises in ovo administration followed by spray administration.
- Claim:
45. The method of claim 42 wherein the administration route comprises spray administration.
- Current International Class:
61; 61; 61; 61; 61; 12; 12
- الرقم المعرف:
edspap.20220409718
Processing Request
No Comments.